Intravenous L-dopa Administration in PD and DLB Patients with Oral Intake Difficulties: Current Status and Challenges
Objective: Investigation of efficacy and challenges of intravenous L-dopa therapy as an alternative treatment for PD patients and those with DLB who experience difficulty with…Positive Relationship Between Improvement in Sleep and Quality of Life During Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion
Objective: To investigate the relationship between improvements in sleep disturbances and quality of life (QoL) in adults with advanced Parkinson’s disease (aPD) treated with a…Unraveling the Variability in Amantadine Response for Levodopa-Induced Dyskinesias: The Impact of Clinical and Genetic Factors
Objective: To identify demographic, clinical, and genetic factors associated with the outcomes of amantadine treatment in dyskinetic Parkinson’s disease (PD) patients. Background: While recent advancements…COMT-Inhibitors Clinical Experience In Early Motor Fluctuations. Six Months Analysis Of REONPARK Study
Objective: The REONPARK study aims to evaluate COMT inhibitors (COMTi) effectiveness and tolerability in alleviating motor complications associated with L-dopa treatment in Parkinson’s disease (PD)…Cognitive Effects of Istradefylline in Parkinson’s Disease: A 26-Week Open-Label Pilot Study
Objective: The objective of this study was to collect preliminary evidence whether istradefylline may improve cognition in Parkinson’s disease (PD) patients with cognitive impairment. Background:…Comparative Safety of Different Routes of Apomorphine Administration in Parkinson’s Disease: A Systematic Review and Meta-Analysis
Objective: To assess the safety profiles of inhaled, sublingual, and subcutaneous apomorphine in patients with Parkinson’s disease (PD). Background: Apomorphine is a direct-acting D1/D2 agonist…Botulinium toxin in treatment of Parkinsonism
Objective: This review discusses the use of BT in various motor and non-motor symptoms of Parkinsonism. This review discusses the use of BT in various…Early Introduction of COMT Inhibitors at Low Levodopa Doses Improves Long-Term Motor Complications in Parkinson’s Disease: A sub-analysis of the REONPARK Study
Objective: This sub-analysis of the REONPARK study aims to identify predictive factors for the greater effectiveness of COMT inhibitors (COMTi) in alleviating motor complications in…VQ-101, a CNS-Penetrant Small Molecule Allosteric Activator of Glucocerebrosidase (GCase), Demonstrates Favorable Tolerability and Sustained Activation of Lysosomal GCase in Individuals with Parkinson’s Disease
Objective: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of VQ-101 in healthy volunteers (HVs), and individuals with Parkinson’s disease (PD) with and without GBA1…COMT-Inhibitors Clinical Experience In Early Motor Fluctuations. Three Months Analysis Of REONPARK Study
Objective: The REONPARK study aims to evaluate COMT inhibitors (COMTi) effectiveness and tolerability in alleviating motor complications associated with L-dopa treatment in Parkinson’s disease (PD)…
- « Previous Page
- 1
- …
- 311
- 312
- 313
- 314
- 315
- …
- 1942
- Next Page »